Search results for "Oral Sprays"

showing 2 items of 2 documents

Fatal hypersensitivity reaction to an oral spray of flurbiprofen: a case report

2013

Summary What is known and objective Safety of the anti-inflammatory drug flurbiprofen is comparable with that of other non-steroidal anti-inflammatory drugs of the propionic acid class, which are commonly associated with gastrointestinal and renal side effects. Here we report a case of a fatal hypersensitivity reaction to an oral spray of flurbiprofen taken for sore throat. Case summary A 29-year-old man came to the emergency care unit reporting sore throat with an intense burning sensation associated with fever. Pharyngotonsillitis was diagnosed, and local treatment with oral flurbiprofen spray was prescribed. Immediately after using the spray, the patient experienced a severe reaction cha…

AdultMaleoral sprayAllergyAdministration TopicalFlurbiprofenAdministration OralFatal hypersensitivity reaction; oral spray; flurbiprofenadverse Effect; adverse reaction; anti inflammatory; fatal reaction; flurbiprofen; hypersensitivity; NSAID; pharmacovigilance; sprayDrug HypersensitivitySettore MED/43 - Medicina LegalemedicineMaculopapular rashSore throatHumansPharmacology (medical)Fatal hypersensitivity reactionCause of deathPharmacologyAsphyxiabusiness.industryAnti-Inflammatory Agents Non-SteroidalPharyngitismusculoskeletal systemmedicine.diseaseflurbiprofenHypersensitivity reactionAnesthesiaItchinglipids (amino acids peptides and proteins)Oral Spraysmedicine.symptombusinessmedicine.drugJournal of Clinical Pharmacy and Therapeutics
researchProduct

Effectiveness of a spray containing 1% malic acid in patients with xerostomia induced by graft-versus-host disease

2018

Background To evaluate the clinical effectiveness of a topical sialogogue spray (malic acid, 1%) in the treatment of xerostomia in patients with chronic Graft versus Host Disease (cGVHD). Material and Methods This study was designed as a randomized double-blind clinical study. Twenty-eight patients with cGVHD suffering from xerostomia were divided into 2 groups: the first group (14 patients) received a topical sialagogue spray containing malic acid 1% (SalivAktive®) whereas the second group (14 patients) received a placebo. Both groups received treatment for 2 weeks. Dry Mouth Questionnaire (DMQ) scores and unstimulated salivary flows rate were collected before and after treatment. Results …

MaleMalatesGraft vs Host DiseaseGastroenterologylaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawSurveys and QuestionnairesMalic acidSialogogueMalic acid; Transplantation; XerostomiaOtorhinolaryngology2734 Pathology and Forensic MedicineMiddle AgedMedically compromised patients in Dentistry:CIENCIAS MÉDICAS [UNESCO]Treatment OutcomeUNESCO::CIENCIAS MÉDICASFemalemedicine.symptomOral SpraysSalivationAdultmedicine.medical_specialtyClinical effectivenessmalic acidPlaceboXerostomia03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansIn patientSalivaGeneral DentistryTransplantationbusiness.industryResearchXerostomia; malic acid; transplantation; Surgery; Otorhinolaryngology2734 Pathology and Forensic Medicine; Dentistry (all)030206 dentistrymedicine.diseaseDry mouthGraft-versus-host diseaseOtorhinolaryngologychemistryDentistry (all)SurgeryMalic acidbusinesstransplantation
researchProduct